Cargando…

ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling

BACKGROUND: Early studies indicated that ASC-J9®, an androgen receptor (AR) degradation enhancer, could suppress the prostate cancer (PCa) progression. Here we found ASC-J9® could also suppress the PCa progression via an AR-independent mechanism, which might involve modulating the tumor suppressor A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Hao, Chou, Fu-ju, Tian, Jing, Zhang, Yong, You, Bosen, Huang, Chi-Ping, Yeh, Shuyuan, Niu, Yuanjie, Chang, Chawnshang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780640/ https://www.ncbi.nlm.nih.gov/pubmed/33390173 http://dx.doi.org/10.1186/s13046-020-01760-2

Ejemplares similares

New therapy with ASC-J9(®) to suppress the prostatitis via altering the cytokine CCL2 signals
por: Lin, Shin-Jen, et al.
Publicado: (2016)

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
por: Chou, Fu-Ju, et al.
Publicado: (2020)

AB130. ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway
por: He, Dalin, et al.
Publicado: (2014)

Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity
por: Chen, Dong, et al.
Publicado: (2022)

Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression
por: Izumi, Kouji, et al.
Publicado: (2013)

ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals
por: Huang, Chi-Ping, et al.
Publicado: (2019)

BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts
por: WEN, SIMENG, et al.
Publicado: (2015)

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression
por: Chou, Fu-Ju, et al.
Publicado: (2019)

Sorafenib with ASC‐J9(®) synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals
por: Xu, Junjie, et al.
Publicado: (2016)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Wang, Keliang, et al.
Publicado: (2020)

Targeting the ERβ/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC
por: Gu, Junfei, et al.
Publicado: (2020)

Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals
por: Deng, Gang, et al.
Publicado: (2021)

Increased CK5/CK8-Positive Intermediate Cells with Stromal Smooth Muscle Cell Atrophy in the Mice Lacking Prostate Epithelial Androgen Receptor
por: Niu, Yuanjie, et al.
Publicado: (2011)

Anti-PTK7 Monoclonal Antibodies Inhibit Angiogenesis by Suppressing PTK7 Function
por: Oh, Si Won, et al.
Publicado: (2022)

Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines
por: Lai, Kuo-Pao, et al.
Publicado: (2012)

Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis
por: Yang, Yang, et al.
Publicado: (2022)

Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation
por: Xu, Hua, et al.
Publicado: (2020)

Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death
por: Xiang, Zhendong, et al.
Publicado: (2021)

Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling
por: Liu, Qing, et al.
Publicado: (2022)

ASC-J9 Blocks Cell Proliferation and Extracellular Matrix Production of Keloid Fibroblasts through Inhibiting STAT3 Signaling
por: Hong, Yi-Kai, et al.
Publicado: (2022)

Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating macrophages with alteration of the TIMP-1/MMP2/MMP9 signals
por: Ding, Xianfan, et al.
Publicado: (2015)

Correction to: Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating acrophages with alteration of the TIMP-1/MMP2/MMP9 signals
por: Ding, Xianfan, et al.
Publicado: (2020)

Sophoridine derivative 6j inhibits liver cancer cell proliferation via ATF3 mediated ferroptosis
por: Tian, Kunpeng, et al.
Publicado: (2023)

PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer
por: Wozniak, Darren J., et al.
Publicado: (2017)

Emerging roles of ATF3 in the suppression of prostate cancer
por: Wang, Ziyan, et al.
Publicado: (2015)

Corrigendum to ‘New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells’
por: Lee, Soo Ok, et al.
Publicado: (2020)

Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer
por: Shang, Zhiqun, et al.
Publicado: (2016)

LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling
por: Luo, Jie, et al.
Publicado: (2019)

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
por: Lin, Changyi, et al.
Publicado: (2020)

High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals
por: Tang, Min, et al.
Publicado: (2022)

C1QBP Regulates YBX1 to Suppress the Androgen Receptor (AR)-Enhanced RCC Cell Invasion()
por: Yue, Dan, et al.
Publicado: (2017)

Interference of PTK6/GAB1 signaling inhibits cell proliferation, invasion, and migration of cervical cancer cells
por: Li, Juan, et al.
Publicado: (2022)

Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression
por: Wu, Gang, et al.
Publicado: (2019)

The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer
por: Liu, Bianjiang, et al.
Publicado: (2020)

TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures
por: Sha, Kai, et al.
Publicado: (2015)

Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR
por: You, Bosen, et al.
Publicado: (2021)

Kinetochore microtubules in PTK cells
Publicado: (1992)

Repeated phototherapeutic keratectomy (PTK) followed by PTK with photorefractive keratectomy for anterior granular corneal dystrophy
por: Sridhar, Uma, et al.
Publicado: (2020)

High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling
por: Chen, Lei, et al.
Publicado: (2022)

Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population
por: Li, Lei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i38hd4oefubj1fao6vll6q25us